Sponsor Dossier
Eli Lilly
Sponsor Dossier for Eli Lilly. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ADCIRCA
- Brand: ALIMTA
- Brand: BASAGLAR
- Brand: CIALIS
- Brand: CYRAMZA
- Brand: EBGLYSS
- Brand: EMGALITY
- Brand: HUMALOG
- Device (sponsor): Basic insulin pen, replaceable-cartridge
About
Eli Lilly Australia Pty Ltd is an Australian Private Company with ABN 39 000 233 992, registered in NSW. The entity is active and registered for GST.
Portfolio
Eli Lilly has 18 brands on the ARTG, of which 18 are indexable and 16 carry a Product Information document. 10 brands are PBS-listed, 16 have a PBAC outcome on record, and 14 have an AusPAR on record. Notable brands include ADCIRCA, ALIMTA, BASAGLAR, CIALIS, CYRAMZA, EBGLYSS, EMGALITY, HUMALOG, HUMULIN, JAYPIRCA, KISUNLA, MOUNJARO.
Therapeutic focus
— Endocrinology: 5 brands — Oncology: 5 brands — Immunology: 2 brands — Neurology: 2 brands — Gastroenterology: 1 brand — Reproductive Health: 1 brand — Dermatology: 1 brand — Cardiology: 1 brand
PBS footprint
10 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2026-07-01, across 16 brands with a PBAC outcome on record. The latest AusPAR is 2026-10-21, across 14 brands with an AusPAR on record.